Shares of Nephrocare Health Services Ltd, the parent of the NephroPlus dialysis services chain, made a strong debut on the stock exchanges on Wednesday, listing at a premium of around 6.9 % over their IPO price of ₹460 per share on the Bombay Stock Exchange (BSE).
The company’s stock opened higher compared with the issue price, reflecting solid investor demand and positive sentiment on its first day of trading after the initial public offering.
The IPO, valued at ₹871 crore, was highly subscribed, with the public issue drawing bids nearly 14 times its offer size, underscoring strong interest from both institutional and retail investors. Nephrocare raised funds through a combination of a fresh issue and an offer for sale by existing shareholders, including private equity investors and promoters.
Coming in ahead of listing, Nephrocare shares had been trading at a decent premium in the grey market, indicating expectations of a positive debut. Investors welcomed the listing performance as a good start for the stock, even as broader market conditions remain watchful.
Nephrocare Health Services operates one of India’s largest organised dialysis networks, and the strong listing reflects confidence in its growth prospects and healthcare franchise positioning.
